Skip to search formSkip to main contentSkip to account menu

dehydroxymethylepoxyquinomicin

Known as: DHMEQ cpd 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

BenzamidesCyclohexanones

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Nuclear factor kappa B inhibition improves conductance artery function in type 2 diabetic mice
2015
2015
Dehydroxymethylepoxyquinomicin selectively ablates T-CAEBV cells.
Chronic active Epstein-Barr virus infection (CAEBV) represents a new subtype of lymphoproliferative disorders characterized by… 
2010
2010
Dehydroxymethylepoxyquinomicin, a novel nuclear factor‐κB inhibitor, prevents inflammatory injury induced by interferon‐γ and histamine in NCTC 2544 keratinocytes
1. The novel nuclear factor (NF)‐κB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) is a derivative of the antibiotic… 
2008
2008
The NF-κB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs
Rituximab in combination with chemotherapy is considered for the treatment of patients with AIDS-associated B-cell non-Hodgkin… 
2006
2006
Control of Allograft Rejection by Applying a Novel Nuclear Factor-&kgr;B Inhibitor, Dehydroxymethylepoxyquinomicin
Background. Nuclear factor (NF)-&kgr;B plays a crucial role in lymphocyte activation, proliferation, and survival. We examined… 
Review
2006
Review
2006
Blocking NF-kappaB as a potential strategy to treat adult T-cell leukemia/lymphoma.
Adult T-cell leukemia/lymphoma (ATL), a fatal T-cell leukemia/lymphoma resistant to chemotherapy, is caused by human T-cell… 
Highly Cited
2005
Highly Cited
2005
In vivo antitumor activity of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia.
Adult T-cell leukemia (ATL) is an aggressive neoplasm caused by human T-cell leukemia virus type I (HTLV-I). The nuclear… 
2005
2005
Inhibition of inflammatory cytokine secretion from mouse microglia cells by DHMEQ, an NF-kappaB inhibitor.
2005
2005
Prevention of Cancer Cachexia by a Novel Nuclear Factor κB Inhibitor in Prostate Cancer
Purpose: To investigate the association between serum interleukin-6 (IL-6) and cachexia in patients with prostate cancer and the… 
2005
2005
Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer.
PURPOSE To investigate the association between serum interleukin-6 (IL-6) and cachexia in patients with prostate cancer and the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)